Moneycontrol
Get App
you are here: HomeNewsBusiness
Last Updated : Mar 30, 2020 10:36 AM IST | Source: PTI

Zydus Cadila gets tentative nod from USFDA for Parkinson's treatment capsule

The approval by the US Food and Drug Administration is for Carbidopa and Levodopa extended-release capsules in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg, Cadila Healthcare said in a regulatory filing.

Representative image
Representative image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Domestic pharma major Zydus Cadila, part of Cadila Healthcare group, on Monday said it has received tentative approval from the US health regulator for its generic version of Parkinson's disease treatment drug Carbidopa and Levodopa extended-release capsules.

The approval by the US Food and Drug Administration is for Carbidopa and Levodopa extended-release capsules in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg, Cadila Healthcare said in a regulatory filing.

This combination medication is indicated for the treatment of Parkinson's disease or Parkinson-like symptoms such as shakiness, stiffness, and difficulty moving and will be manufactured at the group's manufacturing facility at special economic zone (SEZ), Ahmedabad, it added.

Close

The group now has 282 approvals and has so far filed over 386 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04, it said.

Moneycontrol Ready Reckoner
Now that payment deadlines have been relaxed due to COVID-19, the Moneycontrol Ready Reckoner will help keep your date with insurance premiums, tax-saving investments and EMIs, among others.


Facebook-BCG report suggests these measures for businesses to unlock the changing consumer behaviour in the current pandemic. Read More!

First Published on Mar 30, 2020 10:22 am
Sections
Follow us on